Intuitive Surgical's da Vinci Systems Installations Increase Globally
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ISRG?
Source: Fool
- Global Installations Growth: Intuitive Surgical has installed 11,395 da Vinci systems worldwide, reflecting a 12% year-over-year increase, which underscores the company's ability to expand in the rapidly growing surgical robotics sector and strengthens its market leadership.
- Wall Street Analyst Support: Among the 33 analysts covering Intuitive Surgical, 66% have rated it as a buy or strong buy, with an average price target 33% above the current stock price, indicating optimistic expectations for its future growth potential in the market.
- Relatively Cheap Valuation: Intuitive Surgical's price-to-sales, price-to-earnings, and price-to-book ratios are all below their five-year averages, with a current P/E ratio of 52x compared to a five-year average of 70x, suggesting potential upside despite still being considered richly valued.
- Investor Caution Advised: While the company continues to grow rapidly, Intuitive Surgical is currently experiencing a 20% drawdown, having faced multiple similar volatility events in its history, which necessitates that investors possess the ability to endure high volatility to make informed investment decisions in the current market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 428.060
Low
575.00
Averages
637.32
High
740.00
Current: 428.060
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical's da Vinci Systems Installations Increase Globally
- Global Installations Growth: Intuitive Surgical has installed 11,395 da Vinci systems worldwide, reflecting a 12% year-over-year increase, which underscores the company's ability to expand in the rapidly growing surgical robotics sector and strengthens its market leadership.
- Wall Street Analyst Support: Among the 33 analysts covering Intuitive Surgical, 66% have rated it as a buy or strong buy, with an average price target 33% above the current stock price, indicating optimistic expectations for its future growth potential in the market.
- Relatively Cheap Valuation: Intuitive Surgical's price-to-sales, price-to-earnings, and price-to-book ratios are all below their five-year averages, with a current P/E ratio of 52x compared to a five-year average of 70x, suggesting potential upside despite still being considered richly valued.
- Investor Caution Advised: While the company continues to grow rapidly, Intuitive Surgical is currently experiencing a 20% drawdown, having faced multiple similar volatility events in its history, which necessitates that investors possess the ability to endure high volatility to make informed investment decisions in the current market environment.
See More
Johnson & Johnson's Icotyde Shows Strong Potential as a Cash Cow
- New Drug Launch: Johnson & Johnson's newly launched oral medication Icotyde received FDA approval in mid-March for moderate to severe plaque psoriasis, becoming the first oral treatment targeting the IL-23 receptor, and is expected to become a new cash cow for the company.
- Sales Expectations: Icotyde is projected to reach $10.5 billion in sales by 2032, significantly exceeding Wall Street's consensus of $7.4 billion, indicating strong market potential, especially after securing approvals for conditions like Crohn's disease and ulcerative colitis.
- Market Competition: Despite the convenience of Icotyde, analysts express skepticism about its ability to surpass existing biologics like Tremfya and AbbVie's Skyrizi, suggesting that patients may prefer quarterly injections over daily pills.
- Strategic Positioning: J&J's CEO stated that Icotyde, alongside Tremfya, forms a crucial part of the company's immunology portfolio aimed at replacing declining sales from Stelara, which peaked at nearly $11 billion in 2023 but is expected to see significant declines in the future.
See More
U.S. Healthcare Spending to Exceed $3 Trillion
- Healthcare Spending Surge: The Committee for a Responsible Federal Budget projects U.S. healthcare spending to rise from under $2 trillion today to over $3 trillion in a decade, driven by increased use of GLP-1 drugs, rising cancer diagnoses, and a growing number of chronic health issues, indicating significant investment opportunities in the healthcare sector.
- Pfizer's Outlook: Pfizer (PFE) shares fell 0.81% to $25.75, with a market cap of $147 billion; despite declining demand for its vaccine and Paxlovid, its robust drug pipeline and a forward P/E ratio of 9.0, below the five-year average of 9.7, along with a 6.5% dividend yield, provide investors with a solid income while awaiting growth.
- Intuitive Surgical Investment Potential: Intuitive Surgical (ISRG) shares dropped 1.00% to $427.96, with a market cap of $152 billion; although its forward P/E of 44 is below the five-year average of 55, the high price of its robotic surgery systems and 77% recurring revenue make it a compelling investment choice.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) shares fell 0.87% to $1005.16, with a market cap of $948 billion; its Q1 revenue surged 56% year-over-year to $19.8 billion, with adjusted EPS soaring 156%, driven by strong sales of its GLP-1 weight-loss drugs, suggesting that despite a high stock price, its valuation remains attractive.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Intuitive Surgical Faces Challenges and Opportunities
- Market Dominance: Intuitive Surgical's da Vinci system, embedded in the U.S. healthcare ecosystem since its 2000 launch, has an installed base of 11,395 units as of Q1, reflecting a 12% year-over-year increase, which provides a strong economic moat ensuring high customer retention and recurring revenue.
- Diverse Revenue Streams: The company generates significant income from disposable instruments and accessories, which have a high replacement frequency, creating a relatively high-margin recurring revenue source; despite facing tariff impacts, with a projected 1% revenue hit in FY 2026, the long-term revenue growth potential remains substantial as the installed base expands.
- Increasing Competitive Pressure: While Intuitive Surgical leads the robotic-assisted surgery market, threats from competitors like Medtronic are rising, particularly as Medtronic's Hugo system is currently only approved for urologic procedures in the U.S., which could erode market share.
- Long-Term Growth Potential: With the global population aging, the robotic-assisted surgery market is expected to expand significantly, and Intuitive Surgical, with its innovative fifth-generation da Vinci system, is well-positioned to continue innovating and maintaining a competitive edge in this rapidly growing market, attracting long-term investors' interest.
See More
Intuitive Surgical's da Vinci Systems Installations Increase Globally
- Global Installations Growth: Intuitive Surgical has installed 11,395 da Vinci systems worldwide, reflecting a 12% year-over-year increase, which underscores the company's ability to expand in the rapidly growing surgical robotics sector and strengthens its market leadership.
- Wall Street Analyst Support: Among the 33 analysts covering Intuitive Surgical, 66% have rated it as a buy or strong buy, with an average price target 33% above the current stock price, indicating optimistic expectations for its future growth potential in the market.
- Relatively Cheap Valuation: Intuitive Surgical's price-to-sales, price-to-earnings, and price-to-book ratios are all below their five-year averages, with a current P/E ratio of 52x compared to a five-year average of 70x, suggesting potential upside despite still being considered richly valued.
- Investor Caution Advised: While the company continues to grow rapidly, Intuitive Surgical is currently experiencing a 20% drawdown, having faced multiple similar volatility events in its history, which necessitates that investors possess the ability to endure high volatility to make informed investment decisions in the current market environment.
See More
Johnson & Johnson's Icotyde Shows Strong Potential as a Cash Cow
- New Drug Launch: Johnson & Johnson's newly launched oral medication Icotyde received FDA approval in mid-March for moderate to severe plaque psoriasis, becoming the first oral treatment targeting the IL-23 receptor, and is expected to become a new cash cow for the company.
- Sales Expectations: Icotyde is projected to reach $10.5 billion in sales by 2032, significantly exceeding Wall Street's consensus of $7.4 billion, indicating strong market potential, especially after securing approvals for conditions like Crohn's disease and ulcerative colitis.
- Market Competition: Despite the convenience of Icotyde, analysts express skepticism about its ability to surpass existing biologics like Tremfya and AbbVie's Skyrizi, suggesting that patients may prefer quarterly injections over daily pills.
- Strategic Positioning: J&J's CEO stated that Icotyde, alongside Tremfya, forms a crucial part of the company's immunology portfolio aimed at replacing declining sales from Stelara, which peaked at nearly $11 billion in 2023 but is expected to see significant declines in the future.
See More
U.S. Healthcare Spending to Exceed $3 Trillion
- Healthcare Spending Surge: The Committee for a Responsible Federal Budget projects U.S. healthcare spending to rise from under $2 trillion today to over $3 trillion in a decade, driven by increased use of GLP-1 drugs, rising cancer diagnoses, and a growing number of chronic health issues, indicating significant investment opportunities in the healthcare sector.
- Pfizer's Outlook: Pfizer (PFE) shares fell 0.81% to $25.75, with a market cap of $147 billion; despite declining demand for its vaccine and Paxlovid, its robust drug pipeline and a forward P/E ratio of 9.0, below the five-year average of 9.7, along with a 6.5% dividend yield, provide investors with a solid income while awaiting growth.
- Intuitive Surgical Investment Potential: Intuitive Surgical (ISRG) shares dropped 1.00% to $427.96, with a market cap of $152 billion; although its forward P/E of 44 is below the five-year average of 55, the high price of its robotic surgery systems and 77% recurring revenue make it a compelling investment choice.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) shares fell 0.87% to $1005.16, with a market cap of $948 billion; its Q1 revenue surged 56% year-over-year to $19.8 billion, with adjusted EPS soaring 156%, driven by strong sales of its GLP-1 weight-loss drugs, suggesting that despite a high stock price, its valuation remains attractive.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Intuitive Surgical Faces Challenges and Opportunities
- Market Dominance: Intuitive Surgical's da Vinci system, embedded in the U.S. healthcare ecosystem since its 2000 launch, has an installed base of 11,395 units as of Q1, reflecting a 12% year-over-year increase, which provides a strong economic moat ensuring high customer retention and recurring revenue.
- Diverse Revenue Streams: The company generates significant income from disposable instruments and accessories, which have a high replacement frequency, creating a relatively high-margin recurring revenue source; despite facing tariff impacts, with a projected 1% revenue hit in FY 2026, the long-term revenue growth potential remains substantial as the installed base expands.
- Increasing Competitive Pressure: While Intuitive Surgical leads the robotic-assisted surgery market, threats from competitors like Medtronic are rising, particularly as Medtronic's Hugo system is currently only approved for urologic procedures in the U.S., which could erode market share.
- Long-Term Growth Potential: With the global population aging, the robotic-assisted surgery market is expected to expand significantly, and Intuitive Surgical, with its innovative fifth-generation da Vinci system, is well-positioned to continue innovating and maintaining a competitive edge in this rapidly growing market, attracting long-term investors' interest.
See More
